Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: A Gynecologic Oncology Group study
Maurie Markman
, David Spriggs
, Robert A. Burger
, Linda F. Carson
, Samuel S. Lentz
, Holly Gallion
Obstetrics, Gynecology and Women's Health - Gynecologic Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Group Studies
100%
Phase I Trial
100%
Paclitaxel
100%
Ifosfamide
100%
Gynecologic Oncology Group
100%
Pelvic Malignancy
100%
Granulocyte Colony-stimulating Factor (G-CSF)
42%
Marrow Suppression
28%
Malignancy
14%
Chemotherapy Regimen
14%
Chemotherapy
14%
Cervical Cancer
14%
Combination Chemotherapy
14%
Neutropenia
14%
Drug Administration
14%
Treatment Schedule
14%
Administration Sequences
14%
Severe Neutropenia
14%
Mesna
14%
Dose Level
14%
Gynecologic Malignancies
14%
Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
Ifosfamide
100%
Paclitaxel
100%
Granulocyte Colony Stimulating Factor
42%
Chemotherapy
28%
Neutropenia
28%
Drug Administration
14%
Coenzyme M
14%
Uterine Cervix Cancer
14%